The Impact of Patient Adherence on Physician Performance Measurement

Michael B. Nichol, Ph.D. Pharmaceutical Economics and Policy University of Southern California



Presentation Objectives

- The nature of the problem: Why do adherence and persistence impact P4P?
- The problem metric: How do we measure adherence and persistence?
- The population: Who adheres or persists?
- Solving the problem: What can we do to improve our performance, especially for P4P?



Definitions


- Why are we going to use compliance and adherence interchangeably?
- Compliance = whether patients follow the instructions of their doctor
 - □ Dichotomous measure
- Adherence = whether patients endorse the instructions of their doctor
 - Dichotomous measure
- Persistence = how long they follow the advice (whether they modify it over time)
 - □ dichotomous or continuous



Motivation for Compliance Studies

- General recognition that non-compliance is a problem
- Ultimate goal is to improve health outcome by targeting some patients on modifiable factors to improve compliance
- Different parties in health care have different perspectives and interest (e.g., clinicians, patients, and payers)

Evidence that Non-Compliance is a Problem: Medication Event Monitoring System (MEMS)



Each ● represents one medication event



Administrative Data on Drug Reimbursement

Information about patient's medication acquisition and procurement behavior using pharmaceutical benefit manager (PBM) reimbursement data

Features

- Good snapshot of acquisition in relationship to other mediations
- Affordable
- Reliability can be ascertained
- Insight into dosing intervals

Limitations

- Many confounders
- Selection bias
- Dependent on provider of data
- Retrospective





Advantages of Administrative Claims-based Analyses


- Objective (no recall bias)
- Real-world (not controlled)
- Relatively cheap to obtain
- Large sample
- Multiple outcomes
- Cost analysis
- Pattern recognition



Measuring the Complexity of Non-Compliance











Days Covered for Statins and CCBs



Source: Unpublished data

M

Medication Possession Ratio for Statins/CCBs



Source: Unpublished data



Patterns of Non-Compliance


- 15-20% of first scripts never filled
- Of those filled, 20-35% never fill a second
- Persistence declines slowly after 6 months
- Patients who discontinue rarely restart, at least within a two year window for many chronic problems



Why Do We Care?

- Lack of efficacy from recommended treatment
- Increased mortality and morbidity
- Increased costs
- Inability to meet P4P goals

Health Care Costs Associated with Discontinuation: Hypertension




N=6,430

Source: McCombs JS, Nichol MB, Newman C and Sclar DA: The costs of interrupting antihypertensive drug therapy in a Medicaid population. *Medical Care*, 32(3): 214-226, 1994.



Health Care Costs Associated with Discontinuation: Major Depressive Disorder




N=1,240

Source: McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. *Value in Health*, 2(4): 269-280, 1999.




Efficacy/Goal Relationship





Efficacy/Goal/Adherence Relationship





Impact on P4P Goals: LDL <= 130

- Simulation of impact on P4P LDL goal
- Data source is the IHA 2007 P4P reporting for LDL <= 130</p>
- 84.3% of the cardiovascular population were screened
- Assumes that all patients screened are treated
- Assumes that treatment is 100% efficacious




Impact on P4P Goals: LDL <= 130

Proportion adherent to Rx	All screened treated, Proportion meeting goal	90% screened treated, Proportion meeting goal
baseline	59.6%	59.6%
	(70% "adherent")	(78% "adherent")
80% Rx adherent	67.4%	60.7%
90% Rx adherent	75.9%	68.3%

Source: Table computed from 2007 P4P results provided at iha.org







Causes of Non-Compliance

- Multiple causes with multiple levels
- Many factors may not be observable to researchers (many latent variables)
- Each causal level can be targeted to improve compliance



What Can We Do About Non-Adherence: Targeting for Compliance

- Who is non-compliant?
- Why are they non-compliant?
- How can we change their behavior?
- When can we change their behavior?




Demographic Associations with Adherence

- Few studies show clear correlations with adherence among characteristics like age, gender, education, and socio-economic status
- Correlation between patient education level and adherence is positive, but only for medications to treat chronic disease

DiMatteo MR. Variations in patients' adherence to medical recommendations, *Medical Care*: 42:200-209. 2004


Selected Disease Condition Adherence Rates

Mean Rate





Reasons for Non-Compliance





- Review of 38 meta-analytic reviews of adherence interventions
- Technical Interventions (simplifying medication regimen; electronic monitoring)
 - □ Less frequent dosing = improved adherence
 - □ Single dose/day better than multiple doses/day
 - □ Electronic device improvements attributed to reduction in doses

Van Dulmen S, et al. Patient adherence to medical treatment: A review of reviews, *BMC Health Services Research*, 7:55, 2007



- Behavioral Interventions (memory aids, monitoring by calendars, support or rewards)
 - □ Financial rewards improved adherence in 10/11 studies
 - Mail and telephone reminders can improve adherence



- Educational Interventions (teaching/providing knowledge, including personal, group, audio-visual, home visits)
 - □ Effects can be important in the short term, but decay over time (> 4 weeks)
 - □ When tested against dosing simplification, educational interventions less robust
 - □ Collaborative care (systematic inclusion of multiple providers) superior to education alone intervention

Van Dulmen S, et al. Patient adherence to medical treatment: A review of reviews, *BMC Health Services Research*, 7:55, 2007



- Social Support Interventions (practical, emotional, undifferentiated)
 - Large effect sizes seen with social support in welldesigned studies



- Complex or Multi-faceted Interventions (combine multiple approaches)
 - Less than half resulted in improved adherence, and only a third better treatment outcomes
 - □ Successful interventions very resource intensive
 - □ Even the most effective did not yield large effect sizes
 - Variability in intervention and study design compromises assessment

Van Dulmen S, et al. Patient adherence to medical treatment: A review of reviews, *BMC Health Services Research*, 7:55, 2007



Intervention Effects: Largest to Smallest

- Reduced drug dose frequency
- Financial rewards
- Prompting devices
- Adherence-enhancing packaging
- Telephone calls
- Personal counseling
- Home visits
- Reminder letters
- Written education material



Pitfalls to Avoid

- Starting with the intervention "concept"
- Doing too little
- Intervening too late
- Preaching to the choir
- Not from a trusted source
- Measurement via self-report
- Broad intervention population



Recommendations for Improving Adherence to Chronic Medications

- Low hanging fruit
 - Quick follow-up by medical staff after initial prescription (not automated calls)
 - Only apply sampling for cost reasons
 - Get the discontinuers back!



Recommendations for Improving Adherence to Chronic Medications

- Medium term
 - □ Screen for depression
 - □ Build IT capacity to support clinical staff
- Long term
 - □ Targeted populations
 - Medical Home
 - □ Social support



Conclusions

- Non-compliance remains an on-going and significant problem in health care
- The factors associated with non-compliance are now being investigated
- Literature reviews indicate that largest effect sizes will be produced by complex or multi-faceted interventions
- Multiple longitudinal interventions may be required to obtain positive results
- Non-compliance can significantly affect attainment of P4P goals